Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy
- PMID: 23348204
- PMCID: PMC3728887
- DOI: 10.1097/PAS.0b013e31826c1761
Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy
Abstract
Most gastrointestinal stromal tumors (GISTs) can be recognized by their monotonous cytologic features and overexpression of KIT oncoprotein. Altered morphology and loss of CD117 reactivity has been described previously after chronic imatinib treatment; however, this phenomenon has not been reported in imatinib-naive tumors. Eight patients with abrupt transition from a classic CD117-positive spindle cell GIST to an anaplastic CD117-negative tumor were investigated for underlying molecular mechanisms of tumor progression. Pathologic and molecular analysis was performed on each of the 2 components. Genomic DNA polymerase chain reaction for KIT, PDGFRA, BRAF, and KRAS hot spot mutations and fluorescence in situ hybridization for detecting KIT gene copy number alterations were performed. TP53 mutational analysis was performed in 5 cases. There were 7 men and 1 woman, with an age range of 23 to 65 years. Five of the primary tumors were located in the stomach, and 1 case each originated in the small bowel, colon, and rectum. In 3 patients, the dedifferentiated component occurred in the setting of imatinib resistance, whereas the remaining 5 occurred de novo. The dedifferentiated component had an anaplastic appearance, including 1 angiosarcomatous phenotype, with high mitotic activity and necrosis, and showed complete loss of CD117 (8/8) and CD34 (5/8) expression and de novo expression of either cytokeratin (4/8) or desmin (1/8). There was no difference in the KIT genotype between the 2 components. However, 2 imatinib-resistant tumors showed coexistence of KIT exon 11 and exon 13 mutations. Fluorescence in situ hybridization showed loss of 1 KIT gene in 3 cases and low-level amplification of KIT in 2 other cases in the CD117-negative component, compared with the CD117-positive area. TP53 mutation was identified in 1/5 cases tested, being present in both components. In summary, dedifferentiation in GIST may occur either de novo or after chronic imatinib exposure and can represent a diagnostic pitfall. This phenomenon is not related to additional KIT mutations, but might be secondary to genetic instability, either represented by loss of heterozygosity or low level of KIT amplification.
Conflict of interest statement
The authors have no conflicts of interest or funding to disclose.
Figures



Similar articles
-
Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.Clin Transl Oncol. 2012 Aug;14(8):619-29. doi: 10.1007/s12094-012-0851-x. Epub 2012 Jul 18. Clin Transl Oncol. 2012. PMID: 22855146
-
Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.Genes Chromosomes Cancer. 2008 Oct;47(10):853-9. doi: 10.1002/gcc.20589. Genes Chromosomes Cancer. 2008. PMID: 18615679 Free PMC article.
-
Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.Cell Mol Biol (Noisy-le-grand). 2020 Dec 31;66(8):26-32. Cell Mol Biol (Noisy-le-grand). 2020. PMID: 34174973
-
[Translational research and diagnosis in GIST].Pathologe. 2012 Nov;33 Suppl 2:273-7. doi: 10.1007/s00292-012-1682-9. Pathologe. 2012. PMID: 22968735 Review. German.
-
Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.J Gastrointestin Liver Dis. 2013 Dec;22(4):413-8. J Gastrointestin Liver Dis. 2013. PMID: 24369323 Review.
Cited by
-
Gastrointestinal Stromal Tumor With Chondrosarcomatous Dedifferentiation Following Imatinib Therapy.Cureus. 2021 Aug 25;13(8):e17448. doi: 10.7759/cureus.17448. eCollection 2021 Aug. Cureus. 2021. PMID: 34589354 Free PMC article.
-
Frequency and clinicopathologic profile of PIK3CA mutant GISTs: molecular genetic study of 529 cases.Mod Pathol. 2016 Mar;29(3):275-82. doi: 10.1038/modpathol.2015.160. Epub 2016 Jan 22. Mod Pathol. 2016. PMID: 26796526 Free PMC article.
-
Correlation between important genes of mTOR pathway (PI3K and KIT) in Iranian women with sporadic breast cancer.Med J Islam Repub Iran. 2018 Dec 31;32:135. doi: 10.14196/mjiri.32.135. eCollection 2018. Med J Islam Repub Iran. 2018. PMID: 30815430 Free PMC article.
-
The Relationship between KIT Copy Number Variation, Protein Expression, and Angiogenesis in Sporadic Breast Cancer.Rep Biochem Mol Biol. 2020 Apr;9(1):40-49. doi: 10.29252/rbmb.9.1.40. Rep Biochem Mol Biol. 2020. PMID: 32821750 Free PMC article.
-
FGFR2::TACC2 fusion as a novel KIT-independent mechanism of targeted therapy failure in a multidrug-resistant gastrointestinal stromal tumor.Genes Chromosomes Cancer. 2022 Jul;61(7):412-419. doi: 10.1002/gcc.23030. Epub 2022 Feb 22. Genes Chromosomes Cancer. 2022. PMID: 35170141 Free PMC article.
References
-
- Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–580. - PubMed
-
- Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001;61:8118–8121. - PubMed
-
- Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708–710. - PubMed
-
- Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2004;28:889–894. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous